Search hospitals

>

Illinois

>

Elmhurst

Elmhurst Memorial Hospital

Claim this profile

Elmhurst, Illinois 60126

Global Leader in Breast Cancer

Global Leader in Lung Cancer

Conducts research for Breast cancer

Conducts research for Prostate Cancer

Conducts research for Cancer

91 reported clinical trials

14 medical researchers

Photo of Elmhurst Memorial Hospital in ElmhurstPhoto of Elmhurst Memorial Hospital in ElmhurstPhoto of Elmhurst Memorial Hospital in Elmhurst

Summary

Elmhurst Memorial Hospital is a medical facility located in Elmhurst, Illinois. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Prostate Cancer, Cancer and other specialties. Elmhurst Memorial Hospital is involved with conducting 91 clinical trials across 126 conditions. There are 14 research doctors associated with this hospital, such as Brian C. Myre, Samir D. Undevia, Maria I. Quejada, and Sania S. Raza.

Area of expertise

1

Breast Cancer

Global Leader

Elmhurst Memorial Hospital has run 27 trials for Breast Cancer. Some of their research focus areas include:

HER2 negative
ER positive
PR positive
2

Lung Cancer

Global Leader

Elmhurst Memorial Hospital has run 16 trials for Lung Cancer. Some of their research focus areas include:

Stage II
Stage I
Stage IV

Top PIs

Clinical Trials running at Elmhurst Memorial Hospital

Ovarian Cancer

Kidney Cancer

Breast Cancer

Prostate Cancer

Cancer

Bladder Cancer

Cutaneous Melanoma

Melanoma

Pancreatic Carcinoma

Renal Cell Carcinoma

Image of trial facility.

Olaparib +/- Bevacizumab

for Ovarian Cancer

This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving olaparib for one year with or without bevacizumab may be effective in treating patients with BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer, when compared to two years of olaparib.

Recruiting

2 awards

Phase 3

4 criteria

Image of trial facility.

Surgical Procedures

for Reducing Ovarian Cancer Risk

This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk reduction for women with BRCA1 mutations.

Recruiting

1 award

N/A

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Elmhurst Memorial Hospital?